Board Change

London, UK, 9 January 2007 - Lombard Medical Technologies PLC (“Lombard Medical”) today announces that Nigel Gray has retired from his position as a Non-executive Director of the Company.

 

Nigel was appointed at the time of Lombard Medical’s listing on AIM last year. Due to personal commitments, he is not able to devote the necessary time to properly fulfil his responsibilities as a Non-executive Director during a period of rapid change for the Company.  He therefore believes that it is in the Company’s best interest for him to step down from the Board.

 

Alistair Taylor, Executive Chairman of Lombard Medical, said:

“On behalf of the Board I would like to thank Nigel for his contribution to Board discussions and the guidance that he has given the Company over the last year.”

 

Enquiries:

Lombard Medical Technologies PLC  Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Tim Hall, Finance Director

 

Financial Dynamics  Tel: 020 7831 3113
David Yates / John Gilbert

 

Notes to editors

About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease.  The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death.  Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010.  Aorfix™ is currently being commercialised in the EU, with US clinical trials having commenced during 2006.  The Company’s Polymer Coatings Division primarily develops polymer coatings for use in drug eluting stents and has a number of research collaborations developing novel products for this $6bn market.

 

Lombard Medical has recently successfully completed its initial public offering on AIM and was admitted to listing in December 2005, raising £23.9 million, net of expenses.  The Company, based in Oxfordshire, Yorkshire and Boston, USA, employs over 90 people.

 

Further background on the Company can be found at www.lombardmedical.com.

 



Date   

Title

12/10/2008 11:09:00 AM
EndoRefix™ Trial Suspended
11/26/2008 10:40:00 AM
Growing positive experience of Aorfix™ across the world - Approval received for Aorfix™ in Russia
11/24/2008 4:19:00 PM
US Trial and Further Cost Cutting Measures
10/17/2008 5:06:00 PM
Update
9/26/2008 10:46:00 AM
£1.6 million fundraising
9/22/2008 11:22:00 AM
European Arbiter II Trial Completes Recruitment
8/15/2008 6:14:00 PM
Interim Results for the six months ended June 2008
5/12/2008 12:10:00 PM
AGM Trading Update
4/30/2008 11:22:00 AM
US EndoRefix™ Pivotal Trial commences
4/16/2008 12:16:00 PM
FDA Acceptance for Aorfix™ as a Modular PMA and Successful Charing Cross Symposium
3/20/2008 11:27:00 AM
Preliminary Results for Year ended 31 December 2007
1/16/2008 11:29:00 AM
Lombard Directors' Share Purchase
1/14/2008 12:38:00 PM
Result of Lombard EGM and Company Strategy Update
1/8/2008 3:00:00 PM
NHS screening programme for treatment of AAA
12/20/2007 10:22:00 AM
Fundraising of £7.6 million
11/19/2007 11:15:00 AM
Aorfix™ successfully passes 21- patient case review by FDA
10/22/2007 12:31:00 PM
CE Mark and conditional IDE approval received for second-generation EndoRefix™
9/20/2007 11:34:00 AM
Lombard Medical Announces board changes
9/20/2007 11:23:00 AM
Lombard Medical Announces interim results 2007
7/30/2007 11:12:00 AM
Lombard Medical Receives Full FDA Approval of its Supplemental IDE to Pivotal US Clinical Trial
7/13/2007 10:19:00 AM
First US Case in a Patient with a High Angle Neck Aneurysm using Gen II Aorfix™
7/5/2007 3:27:00 PM
Lombard Medical enters into Collaboration with Smith & Nephew to Develop Bioresorbable Drug-eluting Coronary Stents
6/20/2007 1:42:00 PM
Lombard Medical Announces the Acquisition of Culzean Medical Devices Limited
6/15/2007 12:51:00 PM
Lombard Medical Placing announcement
6/15/2007 12:34:00 PM
Lombard Medical announces 2006 Results
5/31/2007 11:52:00 AM
Lombard Medical Receives Conditional FDA Approval of its Supplemental IDE to Pivotal US Clinical Trial
5/22/2007 12:23:00 PM
First Cases for Aorfix™ in Brazil
4/23/2007 6:35:00 PM
Lombard Medical Announces Filing of Supplemental IDE to Pivotal US Clinical Trial for Aorfix™ and Provides Progress Update
4/4/2007 1:24:00 PM
Lombard Medical receives FDA approval of its Supplemental IDE to use "Gen II" Aorfix™ in Pivotal US Clinical Trial
2/23/2007 11:06:00 AM
Trade Investment in Endoart SA
2/12/2007 12:27:00 PM
Yorkshire Forward Grant for Development of Urinary Catheters
2/5/2007 12:22:00 PM
Successful Clinical Cases
1/30/2007 12:00:00 PM
Recommencement of European Clinical Procedures For Second Generation Stent Graft
1/9/2007 1:52:00 PM
Board Change
12/14/2006 10:18:00 AM
Lombard Medical Announces Strategic Collaboration for its Refix™ Endostapler
12/11/2006 5:00:00 PM
Lombard Medical Technologies PLC Total Voting Rights and Share Capital
12/11/2006 4:47:00 PM
Temporary Suspension of European Clinical Procedures For Second Generation Stent Graft
11/10/2006 12:04:00 PM
Lombard Medical announces receipt of CE Mark for its Refix™ Endostapler
11/8/2006 2:23:00 PM
Lombard Medical receives conditional FDA approval of its supplemental IDE for Aorfix™
10/2/2006 12:59:00 PM
Lombard Technologies PLC announces a Collaboration for the Development of a Next Generation Regenerative Stent
9/11/2006 10:32:00 AM
Positive 24 month Clinical Data for Aorfix™ Stent Graft
8/25/2006 10:42:00 AM
Lombard Medical Technologies PLC Trading Update
8/25/2006 10:15:00 AM
Lombard Medical Technologies PLC retains distribution rights for Aorfix™, AAA and Thoracic Stent Grafts
8/3/2006 1:27:00 PM
Lombard Medical enters into collaboration with Axordia for stem cell derived drug eluting stents
5/10/2006 10:31:00 AM
Annual General Meeting
4/13/2006 3:30:00 PM
Positive 12 month Clinical Data for Aorfix™ Stent Graft
4/4/2006 5:07:00 PM
Research Agreement with Amgen and University of Sheffield
3/24/2006 4:44:00 PM
Company Completes Successful Year
2/24/2006 10:59:00 AM
CE Mark and conditional IDE approval received for second-generation EndoRefix™
2/17/2006 2:25:00 PM
Lombard Medical receives full IDE approval for its US clinical trial of its Aorfix™ stent graft
2/15/2006 9:22:00 PM
Application for admission of ordinary shares
2/10/2006 9:18:00 PM
Lombard Medical Announces that Abdominal Aortic Aneurysm Screening to Commence in the US
1/19/2006 2:41:00 PM
Lombard Medical reports new data demonstrating that its Aorfix™ stent graft reduces the risk of endoleaks in angulated necks
1/19/2006 2:16:00 PM
Directors share purchase
1/17/2006 3:43:00 PM
Application for admission of ordinary shares
12/13/2005 3:46:00 PM
Lombard Medical Technologies PLC commences trading on AIM
12/7/2005 9:08:00 PM
Lombard Medical Technologies PLC raises £26.2 million on successful completion of IPO